Shareholder Composition

As of December 31, 2025, the Company’s shareholder composition is as follows:

  • More details click here
Shareholder Rights Protection

CHA Biotech is committed to safeguarding the rights of its shareholders through the following measures.

  • More details click here
    General Meeting of Shareholders
    To protect shareholders’ rights and facilitate their decision-making, the Company adopted an electronic voting system pursuant to Article 368-4 of the Commercial Act and an electronic proxy solicitation system pursuant to Article 160(5) of the Enforcement Decree of the Capital Markets Act by a resolution of the Board of Directors on February 29, 2016. The Company duly informs shareholders of electronic voting and electronic proxy solicitation through the notice of convocation and announcements on the Company’s website.
    Electronic Voting and Proxy Solicitation
    To protect shareholders’ rights and facilitate their decision-making, the Company adopted an electronic voting system pursuant to Article 368-4 of the Commercial Act and an electronic proxy solicitation system pursuant to Article 160(5) of the Enforcement Decree of the Capital Markets Act by a resolution of the Board of Directors on February 29, 2016. The Company duly informs shareholders recorded as of the record date for the General Meeting of Shareholders of matters related to electronic voting and electronic proxy solicitation through the notice of convocation and announcements on the Company’s website.
    Prevention of Information Disparities
    The Company endeavors to provide timely and accurate information to investors by appropriately disclosing the Company’s business status, management strategies, and risks through disclosures, press releases, and its website. In addition, the Company enhances communication channels with investors by providing transparent information through various means, including earnings presentations, IR meetings, and both domestic and international non-deal roadshows (NDR).
Recent Annual General Meeting Results

Below are the voting results from the 24th Annual General Meeting of Shareholders for the 2025 fiscal year, held on March 31, 2026.

  • More details click here
    • 1. Fiscal Year: 24th Fiscal Year (FY2025)
    • 2. Date & Time: March 31, 2026 (Tue) at 10:00 AM
    • 3. Venue: International Conference Hall (B2), Gyeonggi Center for Creative Economy & Innovation,12, Daewangpangyo-ro 645beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
    • 4. Attendance: 36,614,210 shares (45.1% of total outstanding voting shares)
      • Major shareholder & related parties: 28.3%
      • Foreign investors: 4.8%
      • Institutional investors: 2.0%
      • Minority shareholders, etc.: 9.9%
    • 5. Items
      Matters Reported
      • Audit Report (Presented by Kim Chang-ho, Full-time Auditor)
      • Business Report (Presented by Oh Sang-hoon, CEO)
      • Report on the Operation of the Internal Accounting Control System (Presented by Oh Sang-hoon, CEO)
      Resolutions and Results
      • Agenda No. 1: Approval of Financial Statements for the 24th Fiscal Year(January 1, 2025 – December 31, 2025, including the appropriation of retained earnings) ▶Resolution: Approved as proposed(For: 99.9%, Against: 0.1%, Abstained: 0.0%)
      • Agenda No. 2: Amendment to the Articles of Incorporation

        - Agenda No. 2-1-1: Amendment to Article 23 (Number of Directors and Auditor ▶ Resolution: Approved as proposed(For: 89.3%, Against: 10.7%, Abstained: 0.0%)

        Pre-Amendment Provisions Article 23 (Number of Directors and Statutory Auditor) ①The Company shall have not fewer than three (3) and not more than four (4) Directors, and Outside Directors shall constitute at least one-fourth (1/4) of the total number of Directors. The Company shall have one (1) Auditor.
        ② [Deleted] (May 9, 2014)
        Post-Amendment Provisions Article 23 (Number of Directors and Statutory Auditor) ① ① The Company shall have not fewer than three (3) and not more than four (4) Directors, and Independent Directors shall constitute at least one-third (1/3) of the total number of Directors. The Company shall have one (1) Auditor.

        ② [Deleted] (May 9, 2014)
        Purpose of Amendment Clarification of wording (Reflecting amendments to the Commercial Act and the KOSDAQ Standard Articles of Incorporation)

        - Agenda No. 2-1-2: Amendment to Article 23 (Number of Directors and Statutory Auditor) ▶ Resolution: Rejected(For: 11.0%, Against: 89.0%, Abstained: 0.0%)

        Pre-Amendment Provisions Article 23 (Number of Directors and Statutory Auditor) ① The Company shall have not fewer than three (3) and not more than four (4) Directors, and Outside Directors shall constitute at least one-fourth (1/4) of the total number of Directors. The Company shall have one (1) Auditor.

        ② [Deleted] (May 9, 2014)
        Post-Amendment Provisions Article 23 (Number of Directors and Statutory Auditor) ① The Company shall have not fewer than three (3) and not more than twelve (12) Directors, and Outside Directors shall constitute at least one-third (1/3) of the total number of Directors. The Company shall have one (1) Statutory Auditor.

        ② [Deleted] (May 9, 2014)
        Purpose of Amendment Enhancement of management stability and decision-making efficiency Alignment with the intent of amendments to the Commercial Act

        - Agenda No. 2-2: Amendment to Article 32-2 (Committees) ▶ Resolution: Approved as proposed(For: 99.6%, Against: 0.4%, Abstained: 0.0%)

        Pre-Amendment ProvisionsArticle 32-2 (Committees) ① The Company may establish the following committees within the Board of Directors by a resolution of the Board: 1. Management Committee 2. Audit Committee 3. Outside Director Nomination Committee 4. Other committees deemed necessary by the Board
        Post-Amendment ProvisionsArticle 32-2 (Committees) ① The Company may establish the following committees within the Board of Directors by a resolution of the Board: 1. Management Committee 2. Audit Committee 3. Independent Director Nomination Committee 4. Other committees deemed necessary by the Board
        Purpose of AmendmentClarification of wording (Reflecting amendments to the Commercial Act and the KOSDAQ Standard Articles of Incorporation)

        - Agenda No. 2-3: Addition of Supplementary Provisions ▶ Resolution: Approved as proposed(For: 99.6%, Against: 0.4%, Abstained: 0.0%)

        Pre-Amendment Provisions-
        Post-Amendment ProvisionsSupplementary Provisions ① These Articles of Incorporation shall enter into force on March 31, 2026. ② The amended provision of Article 23(1) shall enter into force on July 23, 2026. ③ In the event that Independent Directors are appointed, at least one-third (1/3) of the total number of Directors shall be Independent Directors within July 22, 2027, pursuant to the proviso to Article 2 of the Supplementary Provisions of the Act (Act No. 20991, Jul. 22, 2025).
        Purpose of AmendmentClarification of effective dates

        - Agenda No. 2-4: Establishment of Article 10-5 (Restriction on Issuance of New Shares) (Shareholder Proposal) Resolution: Rejected(For: 11.3%, Against: 88.7%, Abstained: 0.0%)

        Pre-Amendment Provisions-
        Post-Amendment ProvisionsArticle 10-5 (Restriction on Issuance of New Shares) In the event that the Company issues new shares by a resolution of the Board of Directors, such issuance shall be made in accordance with the following methods.Provided, however, that in the event new shares exceeding ten percent (10%) of the total number of issued shares are to be issued, approval by a special resolution of the General Meeting of Shareholders shall additionally be required.
        Purpose of AmendmentPrevention of dilution of share value caused by excessive capital increases

        - Agenda No. 2-5: Establishment of Article 17-2 (Advisory Shareholder Proposal) (Shareholder Proposal) ▶ Resolution: Rejected(For: 11.7%, Against: 88.3%, Abstained: 0.0%)

        Pre-Amendment Provisions-
        Post-Amendment Provisions Article 17-2 (Advisory Shareholder Proposal) ① A shareholder who holds shares representing at least three percent (3%) of the total number of issued shares excluding non-voting shares, or a shareholder who has continuously held shares representing at least one percent (1%) of the total number of issued shares excluding non-voting shares for at least six (6) months, may propose to the directors, in writing or by electronic document, at least six (6) weeks prior to the date of the General Meeting of Shareholders (in the case of an annual general meeting, the corresponding date of the previous year’s annual general meeting; hereinafter the same shall apply in this Article), that matters relating to the Company’s capital structure or financing, restructuring of corporate governance, executive compensation policies, or shareholder return policies be included as agenda items of the General Meeting of Shareholders, even if such matters are not designated as matters to be resolved by the General Meeting of Shareholders under applicable laws or the Articles of Incorporation (hereinafter referred to as “Advisory Shareholder Proposal”).

        ② A shareholder under Paragraph 1 may request that the Company include, in the notices and public announcements under Article 363 of the Commercial Act and Article 17 of the Articles of Incorporation, a summary of the proposal submitted by such shareholder, together with the matters proposed as agenda items, by submitting such request in writing or by electronic document at least six (6) weeks prior to the date of the General Meeting of Shareholders.

        ③ Where an Advisory Shareholder Proposal is made, the directors shall report it to the Board of Directors, and the Board of Directors shall include it as an agenda item of the General Meeting of Shareholders unless the content of such proposal violates applicable laws or the Articles of Incorporation. In such case, if requested by the proposing shareholder, such shareholder shall be given an opportunity to explain the proposal at the General Meeting of Shareholders.

        ④ Resolutions of the General Meeting of Shareholders regarding Advisory Shareholder Proposals shall be made in accordance with Article 19.

        ⑤ If an Advisory Shareholder Proposal is approved at the General Meeting of Shareholders, the Company shall report on the implementation status and details thereof at the first annual general meeting following the meeting at which the proposal was made, and if not implemented, the Company shall report and disclose the specific reasons therefor.
        Purpose of AmendmentEnhancement of shareholder value and corporate value

        - Agenda No. 2-6: Amendment to Article 21 (Voting Rights) (Shareholder Proposal) ▶ Resolution: Rejected(For: 13.9%, Against: 86.1%, Abstained: 0.0%)

        Pre-Amendment ProvisionsArticle 21 (Voting Rights) ① Each share shall have one (1) vote at the General Meeting of Shareholders. ② The Company shall not apply the cumulative voting system pursuant to Article 382-2 of the Commercial Act in the election of directors.
        Post-Amendment Provisions Article 21 (Voting Rights) ① Each share shall have one (1) vote at the General Meeting of Shareholders. ② The Company shall apply the cumulative voting system pursuant to Article 382-2 of the Commercial Act in the election of directors.
        Purpose of Amendment Restoration of shareholder value and alignment with amendments to the Commercial Act
      • Agenda No. 3 : Appointment of Directors
        -Agenda No. 3-1: Appointment of Inside Director (New): Kyeong Wook Yoon ▶Resolution: Approved as proposed(For: 96.7%, Against: 3.3%, Abstained: 0.0%)
        Name Date of Birth Term New Appointment Nominator
        Kyeong Wook Yoon February 14, 1967 3 years New Board of Directors
        Primary Occupation Detailed Career (Past 10 Years) Shareholding
        Period Description
        Chief Executive Officer, CHA AI Healthcare Co., Ltd. / CHA Healthcare Co., Ltd. 2025.10 ~ Present
        2023.09 ~ Present
        2013.08 ~ 2020.05
        2009.03 ~ 2013.07
        2006.01 ~ 2009.02
        Chief Executive Officer, CHA AI Healthcare
        Chief Executive Officer, CHA Healthcare
        Chief Executive Officer, CHA Healthcare
        Head of Strategic Planning Division, CHA Biotech
        Finance Director, CHA Biotech
        None
        Relationship with Major Shareholder None
        Relationship with Company None
        Transactions with Company in the Past 3 Years None
        Record of Tax Delinquency in the Past 5 Years None
        Involvement in Insolvent Companies as an Executive in the Past 5 Years None
        Disqualification under Applicable Laws and Regulations None
        Name Kyeong Wook Yoon
        Date of Birth February 14, 1967
        Term 3 years
        New Appointment New
        Nominator Board of Directors
        Primary Occupation Chief Executive Officer, CHA AI Healthcare Co., Ltd. / CHA Healthcare Co., Ltd.
        Period 2025.10 ~ Present
        2023.09 ~ Present
        2013.08 ~ 2020.05
        2009.03 ~ 2013.07
        2006.01 ~ 2009.02
        Description Chief Executive Officer, CHA AI Healthcare
        Chief Executive Officer, CHA Healthcare
        Chief Executive Officer, CHA Healthcare
        Head of Strategic Planning Division, CHA Biotech
        Finance Director, CHA Biotech
        Shareholding None
        Relationship with Major Shareholder None
        Relationship with Company None
        Transactions with Company in the Past 3 Years None
        Record of Tax Delinquency in the Past 5 Years None
        Involvement in Insolvent Companies as an Executive in the Past 5 Years None/td>
        Disqualification under Applicable Laws and Regulations None

        - Agenda No. 3-2: Appointment of Independent Director (Shareholder Proposal): Yong Joo Lee ▶Resolution: Rejected(For: 11.3%, Against: 88.7%, Abstained: 0.0%)

        Name Date of Birth Term New Appointment Nominator
        Yong Joo Lee June 15, 1970 3 years New Board of Directors
        Primary Occupation Detailed Career (Past 10 Years) Shareholding
        Period Description
        Office Worker 2003년 ~ Present Secretary General, Saemmul Learning Community 2,501 shares
        Relationship with Major Shareholder None
        Relationship with Company None
        Transactions with Company in the Past 3 Years None
        Record of Tax Delinquency in the Past 5 Years None
        Involvement in Insolvent Companies as an Executive in the Past 5 Years None
        Disqualification under Applicable Laws and Regulations None
        Name Yong Joo Lee
        Date of Birth June 15, 1970
        Term 3 years
        New Appointment New
        Nominator Board of Directors
        Primary Occupation Office Worker
        Period 2003년 ~ Present
        Description Secretary General, Saemmul Learning Community
        Shareholding 2,501 shares
        Relationship with Major Shareholder None
        Relationship with Company None
        Transactions with Company in the Past 3 Years None
        Record of Tax Delinquency in the Past 5 Years None
        Involvement in Insolvent Companies as an Executive in the Past 5 Years None
        Disqualification under Applicable Laws and Regulations None
      • Agenda No. 4: Appointment of Statutory Auditor
        - Agenda No. 4-1: Appointment of Full-time Statutory Auditor (New): Jae Ho Lee ▶ Resolution: Approved as proposed(For: 75.7%, Against: 24.3%, Abstained: 0.0%)
        Name Date of Birth Term New Appointment Nominator
        Jae Ho Lee April 2, 1956 3 years New Board of Directors
        Primary Occupation Detailed Career (Past 10 Years) Shareholding
        Period Description
        Audit and Internal Control Expert (Former Senior Auditor, Board of Audit and Inspection of Korea) 2024.04 ~ 2025.01 Senior Advisor, Law Firm KL Partners None
        2018.01 ~ 2021.12 Head of Ethics Management Support Division (Audit, Compliance & Legal), Korea Aerospace Industries, Ltd.
        2014.09 ~ 2017.12 Senior Advisor, Deloitte Korea (Anjin LLC)
        1989.12 ~ 2014.08 Senior Advisor, Deloitte Korea (Anjin LLC)
        Relationship with Major ShareholderNone
        Relationship with CompanyNone
        Transactions with Company in the Past 3 YearsNone
        Record of Tax Delinquency in the Past 5 YearsNone
        Involvement in Insolvent Companies as an Executive in the Past 5 YearsNone
        Disqualification under Applicable Laws and RegulationsNone
        Name Jae Ho Lee
        Date of Birth April 2, 1956
        Term 3 years
        New Appointment New
        Nominator Board of Directors
        Primary Occupation Audit and Internal Control Expert (Former Senior Auditor, Board of Audit and Inspection of Korea)
        Period 2024.04 ~ 2025.01

        2018.01 ~ 2021.12

        2014.09 ~ 2017.12

        1989.12 ~ 2014.08
        Description Senior Advisor, Law Firm KL Partners

        Head of Ethics Management Support Division (Audit, Compliance & Legal), Korea Aerospace Industries, Ltd.

        Senior Advisor, Deloitte Korea (Anjin LLC)

        Senior Advisor, Deloitte Korea (Anjin LLC)
        Shareholding None
        Relationship with Major Shareholder None
        Relationship with Company None
        Transactions with Company in the Past 3 Years None
        Record of Tax Delinquency in the Past 5 Years None
        Involvement in Insolvent Companies as an Executive in the Past 5 Years None
        Disqualification under Applicable Laws and Regulations None

        - Agenda No. 4-2: Appointment of Full-time Statutory Auditor (Shareholder Proposal): Sang Won Hwang ▶Resolution: Rejected(For: 25.1%, Against: 74.9%, Abstained: 0.0%)

        Name Date of Birth Term New Appointment Nominator
        Sang Won Hwang November 11, 1969 3 years New Board of Directors
        Primary Occupation Detailed Career (Past 10 Years) Shareholding
        Period Description
        Certified Public Accountant 2017.04 ~ Present Director, Sejeong Accounting Firm None
        Relationship with Major Shareholder None
        Relationship with Company None
        Transactions with Company in the Past 3 Years None
        Record of Tax Delinquency in the Past 5 Years None
        Involvement in Insolvent Companies as an Executive in the Past 5 Years None
        Disqualification under Applicable Laws and Regulations None
        Name Sang Won Hwang
        Date of Birth November 11, 1969
        Term 3 years
        New Appointment New
        Nominator Board of Directors
        Primary Occupation Certified Public Accountant
        Period 2017.04 ~ Present
        Description Director, Sejeong Accounting Firm
        Shareholding None
        Relationship with Major Shareholder None
        Relationship with Company None
        Transactions with Company in the Past 3 Years None
        Record of Tax Delinquency in the Past 5 Years None
        Involvement in Insolvent Companies as an Executive in the Past 5 Years None
        Disqualification under Applicable Laws and Regulations None
        • Agenda No. 5: Approval of Ceiling on Directors’ Remuneration ▶Resolution: Approved as proposed(For: 80.0%, Against: 20.0%, Abstained: 0.0%)
        • Agenda No. 6: Approval of Ceiling on Statutory Auditor’s Remuneration ▶Resolution: Approved as proposed(For: 99.6%, Against: 0.4%, Abstained: 0.0%)
        • Agenda No. 7: Adoption of Advisory Shareholder Proposal (Shareholder Proposal) ▶Resolution: Not submitted for resolution(Due to the rejection of Agenda No. 2-5)
Dividend Information

CHA Biotech’s dividend-related details are as follows.

  • More details click here
    Dividend History
    Category 24th 23rd 22nd 21st 20th
    (2025) (2024) (2023) (2022) (2021)
    Face Value per Share(KRW) 500 500 500 500 500
    Net Income
    (Separate Financials, KRW 1miilion)
    -28,974 52,696 1,407 -61,893 -8,818
    Total Cash Dividends
    (KRW 1miilion)
    - - - - -
    Total Stock Dividends
    (KRW 1miilion)
    - - - - -
    Cash Dividend Payout Ratio
    (Separate Financials, %)
    - - - - -
    Cash Dividend Yield (%) Common Stock - - - - -
    Preferred Stock - - - - -
    Stock Dividend Yield (%) Common Stock - - - - -
    Preferred Stock - - - - -
    Cash Dividend per Share(KRW) Common Stock - - - - -
    Preferred Stock - - - - -
    Stock Dividend per Share(Shares) Common Stock - - - - -
    Preferred Stock - - - - -
    Dividend Policy
    In accordance with the Company’s articles of incorporation, dividends may be paid in cash or in kind. Pursuant to Article 462 of the Commercial Act, the Company seeks to implement a shareholder return policy through profit distribution while maintaining financial soundness via internal reserves, taking into account the business environment.
    The Company is committed to implementing a shareholder-friendly dividend policy while enhancing corporate value. To this end, it aims to secure competitiveness in its core business of cell therapy development and secure growth engines for sustained profitability.